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A common scenario
A 50-year-old male was found on the street
confused. He had little recollection about the event
but thought he might have passed out. Recently he
has had progressive exertional dyspnea and fatigue
but no other specific complaints. He was admitted
to the hospital for further evaluation and treatment.
Physical examination revealed blood pressure of
120/80 without orthostatic changes. Carotid mas-
sage was negative. The lungs were clear. Cardiac
examination revealed an S3 gallop. There was no
peripheral oedema. ECG showed normal sinus rhy-
thm and a left bundle branch block. Chest x-ray
showed an enlarged heart and vascular redistribu-
tion. The echocardiogram showed a left ventricular
ejection fraction of 35%. Coronary angiography re-
vealed normal coronary arteries. Electrophysiology
study was negative for inducible ventricular arrhy-
thmias. This review addresses issues regarding the
assessment and management of patients such as this
with systolic heart failure and syncope.
Introduction
Syncope is a transient loss of consciousness
and postural tone due to cerebral hypoperfusion
followed by rapid and complete recovery. It is
a common clinical problem that is responsible for
approximately 1–6% of hospital admissions and 3%
of emergency room visits annually in the United
States [1]. Syncope is a nonspecific symptom with
multiple causes ranging from benign to potentially
life threatening. Syncope can be debilitating in na-
ture. It may indicate a poor prognosis.
Syncope and risk of death
The prognostic significance of syncope has
been related primarily to its specific cause and to
the presence of structural cardiac disease [2, 3]. The
presence of structural heart disease has been as-
sociated with increased mortality in patients with
syncope [4–6]. The independent prognostic value
of syncope in patients with structural heart disease
has been questioned in a study by Kapoor and Ha-
nusa [3], in which 470 patients with and without syn-
cope had similar rates of overall and cardiac morta-
lity over one-year follow-up. Underlying heart di-
sease, not syncope, predicted mortality. Only 14.7%
of syncope patients were thought to have a cardiac
cause of syncope. Almost half of the patients were
thought to have a non-cardiac cause for syncope.
The Framingham study [2] indicated that the-
re is a relationship between the presumed cause for
syncope and its prognosis (Fig. 1). Presumed car-
Figure 1. Overall survival of participants with syncope
according to cause, and participants without syncope.
P < 0.001 for the comparison between participants with
and those without syncope. The category “Vasovagal
and other causes” includes vasovagal, orthostatic, me-
dication-induced and other infrequent causes of synco-
pe. Reproduced with permission from [2].
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diac syncope was an independent predictor of the
risk of death (HR 2.01, p < 0.001). Vasovagal syn-
cope was associated with benign prognosis while
syncope of unknown cause carried intermediate risk
for all-cause mortality (HR 1.32, p < 0.01). From
these data, it remained unclear whether syncope
was causally related to the risk of death or an unre-
lated marker of poor prognosis.
Syncope, as a prognostic indicator, may be dise-
ase dependant. Syncope indicates a particularly high
risk of death in patients with specific genetic cardiac
disorders such as arrhythmogenic cardiomyopathies,
short and long QT syndromes and Brugada syndro-
me [7–10]. When present along with other non-inva-
sive risk factors, recurrent syncope is generally ac-
cepted as an indicator of sudden death in patients with
hypertrophic cardiomyopathy [11].
Patients with heart failure
Syncope has been associated with adverse pro-
gnosis in patients with depressed left ventricular func-
tion and heart failure. In a retrospective analysis [12],
60 of 491 patients with NYHA class III–IV heart failu-
re and mean left ventricular ejection fraction of 20%
had syncope. The one-year rate of sudden death was
45% in patients with syncope regardless of cause ver-
sus 12% in patients without syncope (p < 0.00001).
In a multivariate analysis, reduced left ventricular
ejection fraction was the only independent predictor
of sudden death in syncope patients [13].
A post hoc analysis of the Electrophysiologic
Study Versus Electrocardiographic Monitoring
(ESVEM) trial showed that patients with syncope,
structural heart disease (mean left ventricular ejec-
tion fraction of 32%), frequent ventricular ectopy
and inducible ventricular tachycardia at electrophy-
siology study have a similarly high risk of death as
cardiac arrest survivors with similar degrees of left
ventricular dysfunction, ventricular ectopy and elec-
trophysiology test findings. The actuarial 4-year
mortality rate in patients with syncope was 48%
compared to 33% in cardiac arrest survivors [5].
Another line of evidence, suggesting a high risk
of sudden arrhythmic death in heart failure patients
with syncope, comes from studies using analysis of
implantable cardioverter-defibrillator (ICD) data. In
patients with syncope, structural heart disease and
inducible sustained ventricular arrhythmias at elec-
trophysiology testing, appropriate ICD therapies oc-
cur frequently and at rates comparable to patients
with documented spontaneous ventricular arrhyth-
mia [14–16]. Similarly, a high rate of appropriate
ICD therapies has been observed in patients with
syncope, idiopathic dilated cardiomyopathy and ne-
gative electrophysiology testing [6, 17–19].
A major limitation of the ICD-based analysis is
the use of appropriate ICD therapies as a measure
of outcome. Many ventricular tachycardia episodes
terminate spontaneously without event. Therefo-
re, ICD shocks may not be a reliable surrogate for
sudden cardiac death [20, 21]. A recent post hoc
analysis of Defibrillators in Non-Ischemic Cardio-
myopathy Trial Evaluation (DEFINITE) trial, which
evaluated primary prevention ICD strategy in pa-
tients with non-ischemic cardiomyopathy, found
that the rate of appropriate ICD therapies in ICD
patients was twice as high as risk of sudden death
in patients without ICD [20]. These data strongly
suggest that the use of appropriate ICD shocks ove-
restimate the risk of sudden death and mortality
benefit from ICD therapies in syncope patients.
None of the uncontrolled and retrospective stu-
dies were designed to address whether syncope was
an independent prognostic indicator of poor outco-
me in heart failure patients. These issues were re-
cently addressed in a retrospective analysis of the
Sudden Cardiac Death Heart Failure Trial (SCD-
-HeFT) data [22].
The SCD-HeFT was a multicenter, randomi-
zed, controlled clinical trial that evaluated primary
prevention strategy with ICD or amiodarone ver-
sus placebo in patients with ischemic or non-ische-
mic cardiomyopathy, NYHA functional class II–III
heart failure and left ventricular ejection fraction £
£ 35% who were treated with standard heart failu-
re medications. Syncope after randomization (14%
of patients) was a predictor of total mortality (HR
1.41, p = 0.002) and cardiovascular death (HR 1.55,
p = 0.001) but not sudden cardiac death (HR 1.41,
p = 0.13). These data indicate that heart failure pa-
tients with syncope may be at a greater risk of de-
ath than those without syncope (Table 1). Howe-
ver, all syncope patients had similarly poor outco-
mes regardless of treatment arm (ICD, amiodarone,
placebo) suggesting a lack of mortality benefit from
ICDs in these patients [22].
Further studies are warranted to establish the
prognostic significance of syncope in heart failure
patients, to elucidate the casual relationship betwe-
en syncope and increased mortality, and to define
the optimal therapeutic strategy.
Evaluation of syncope in
patients with heart failure
No universally applicable “cookbook” approach
exists to evaluate syncope in heart failure patients.
The cause for syncope can be difficult or even im-
possible to diagnose even after an extensive work-
up. The history and the physical exam are the key
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to the diagnosis. A careful history and physical exa-
mination can identify a cause for syncope in up to
50% of cases. However, no symptom appears to be
able to predict mortality or syncope recurrence [23].
The history should focus on establishing whe-
ther the event was truly syncope and if so, should
identify clues that might point towards a specific
etiology. Old records (and outside records) should
be reviewed for clues. Further evaluation is guided
by clinical findings derived from the patient’s histo-
ry and physical examination. The following clinical
features may indicate a higher risk of a cardiac cau-
se for syncope: the presence of heart disease, male
gender, family history of syncope or sudden death,
blurred vision, syncope during exertion or while
supine, and a history of antecedent palpitations or
chest pain [24].
The presence of heart disease does not neces-
sarily indicate that syncope has a cardiac cause [24].
Nevertheless, sudden unexpected loss of conscio-
usness without prodrome in a patient with heart
failure is very worrisome and could indicate an ar-
rhythmic cause or sudden hemodynamic collapse.
If this is the case, the patient should be admitted to
the hospital and evaluated while being monitored.
In patients with diagnosed or suspected heart
failure, careful physical examination is crucial to
determine the extent of the heart failure and how
sick the patient is. Evaluation should consider or-
thostatic vital signs. The cardiac examination may
reveal a murmur suggestive of aortic stenosis or
hypertrophic cardiomyopathy, systemic or orthosta-
tic hypotension, tachycardia or rhythm disturbances.
Diagnostic testing should be selective and gu-
ided by findings from the patient’s history and phy-
sical examination. In cases of syncope, electrocar-
diogram (ECG) and echocardiogram are the next
logical steps for patients suspected of having heart
failure, after a history and physical examination are
obtained. The ECG may indicate the underlying
cause with findings such as sinus bradycardia, he-
art block, intraventricular conduction abnormalities,
abnormal QT intervals, myocardial infarction, Bru-
gada pattern, Wolff-Parkinson-White pattern or ri-
ght ventricular cardiomyopathy. An abnormal ECG,
however, is a non-specific finding.
In case of intermittent symptoms, correlating
the event with a cardiac rhythm disturbance sho-
uld be sought by means of monitoring. Ambulatory
ECG monitoring, either continuous (24–48 h Hol-
ter) or patient-triggered event monitoring, are of
low value if the episodes are rare. External loop mo-
nitoring is limited by the inability of many syncope
patients to activate the device in a timely fashion.
The diagnostic yield of external recording devices
for arrhythmia detection has recently been impro-
ved by auto-triggering as well as by continuous ECG
transmission to a central monitoring station (so-
called mobile cardiac outpatient telemetry) [25, 26].
Implantable loop recorders are effective in patients
with infrequent but worrisome symptoms [27, 28].
The role of other non-invasive tests in evalu-
ating syncope in heart failure is unclear. Some pre-
liminary data suggest that patients with idiopathic
dilated cardiomyopathy and unexplained syncope
commonly have a positive tilt test [29]. Nonethe-
less, some important issues concerning the use of
the test in heart failure patients with syncope, such
as optimal protocol, diagnostic value and long-term
prognostic significance of positive results as well
as optimal therapeutic strategy for patients with
a positive test, remain to be determined. The utili-
ty of risk stratification methods such as microvolt
T-wave alternans specifically for the evaluation of
syncope in heart failure is uncertain.
The type and extent of heart disease needs to
be characterized. The patient should be evaluated
and treated appropriately for their underlying he-
art disease. For heart failure patients, an arrhyth-
mic cause for syncope should always be seriously
Table 1. Syncope after randomization predicts death. Reproduced with permission from [22].
BY TREATMENT ARM
Syncope Amiodarone Placebo ICD
HR (95% CI) 1.33 (0.91–1.93) 1.39 (0.96–2.02) 1.54 (1.04–2.27)
BY CAUSE OF DEATH
Syncope All-cause mortality Cardiovascular mortality Sudden death
HR (95% CI) 1.41 (1.13–1.76) 1.55 (1.19–2.02) 1.41 (0.90–2.21)
p 0.002 0.001 0.13
CI — confidence interval; HR — hazard ratio; ICD — implantable cardioverter-defibrillator
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considered. If left ventricular function is reduced,
an ICD implant should be considered based on stan-
dard implant recommendations (independent of the
presence of syncope).
If the patient does not meet the criteria for an
ICD and appears to be at low risk of sudden death,
long-term monitoring with an external or implanta-
ble device would be an appropriate next step. This
may be a patient with heart failure symptoms and
a relatively well-preserved left ventricular ejection
fraction. For patients with moderately impaired ven-
tricular systolic function, a bundle branch block, wor-
sening heart failure symptoms, evidence for ventri-
cular ectopy or recurrent nonsustained ventricular
tachycardia on the monitor, electrophysiology testing
should be considered. While the electrophysiology
test may lack sensitivity and specificity, it is an im-
portant step in the evaluation process.
The role of electrophysiology testing
Electrophysiology testing helps risk stratify
syncope patients with heart failure, but this is di-
sease dependant; overall, its diagnostic and
predictive value is limited. The prognostic value
is best for patients with ischemic heart disease
[30]. Inducible ventricular or supraventricular ta-
chyarrhythmias and some bradycardia [31] can
provide a presumptive cause for syncope. With
respect to the type of induced ventricular tachy-
arrhythmia, inducible monomorphic ventricular
tachycardia is the most specific when compared
to induction of nonsustained ventricular tachycar-
dia, polymorphic ventricular tachycardia or ven-
tricular fibrillation [32].
Patients with syncope, heart failure and impa-
ired left ventricular function, regardless of the etio-
logy of their heart disease, are at high risk for sud-
den death and total mortality whether they have in-
ducible ventricular arrhythmias or not [33]. The test
has a particularly low negative predictive value and
is not useful for risk stratifying patients with non-
ischemic cardiomyopathy [30]. The test has little or
no value in patients with hypertrophic or arrhythmo-
genic right ventricular cardiomyopathies [11, 34].
Currently, electrophysiology testing is rarely
performed in patients with depressed left ventricu-
lar systolic function and heart failure who would
otherwise be candidates for primary prevention
ICDs regardless of syncope. The test is generally
reserved for patients with organic heart disease or
conduction system abnormalities who do not meet
criteria for ICD placement.
Electrophysiology testing can be helpful to
evaluate conduction system abnormalities in syn-
cope patients with bundle branch block, prolonged
PR interval, episodic AV block and sinus pauses,
but the test lacks the sensitivity to detect most
causes for bradycardia. A prolonged HV interval
and/or procainamide induced infra-Hisian block has
been associated with a high risk of subsequent AV
block [35].
A quarter of patients with HV interval > 100 ms
developed AV block over a follow up period of
30 months [36]. A prolonged HV interval (usually
> 100 ms) suggests heart block as the etiology of
syncope but does not necessarily imply causality.
Some data indicate that electrophysiology testing
is relatively insensitive for identifying clinically si-
gnificant bradycardia [37, 38]. In a study by Brignole
et al. [37], almost a third of patients with recurrent
syncope, bundle branch block and a negative elec-
trophysiology test had transient AV block documen-
ted by an implantable loop recorder.
The 2006 ACC/AHA/ESC guidelines recom-
mend electrophysiologic testing for evaluation of
syncope in the following situations: Class I: elec-
trophysiology testing is recommended in patients
with syncope of unknown cause with impaired left
ventricular function or structural heart disease (le-
vel of evidence: B). Class IIa: electrophysiology te-
sting can be useful in patients with syncope when
bradyarrhythmias or tachyarrhythmias are suspec-
ted and in whom non-invasive diagnostic studies are
not conclusive (level of evidence: B).
Let us consider a 55-year-old male patient who
has ischemic dilated cardiomyopathy but has recur-
rent syncope. Electrocardiogram shows left bundle-
branch block, and echocardiogram shows a left ven-
tricular ejection fraction of 40%. In further evalu-
ation of this patient it may be worth performing an
electrophysiology study since he would not meet
the criteria for a primary prevention ICD in any
event and may not benefit from one. He should,
however, be treated with proper medical therapy
including a beta-blocker and an angiotensin conver-
ting enzyme inhibitor. In this case, an electrophy-
siology study is performed and shows an HV inte-
rval of 180 ms (Fig. 2) and inducible sustained mo-
nomorphic ventricular tachycardia (Fig. 3). In this
case, the patient would be a candidate for an ICD.
However, it remains unclear whether his syncope
has been due to bradycardia or tachycardia or some
other cause including hemodynamic collapse.
The role of ICDs
ICDs can play an important role in reducing the
risk of total mortality in patients with heart failure.
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This role is independent of the presence or absen-
ce of syncope. Any clinical decision made regarding
the use of an ICD in a heart failure patient must first
include consideration of the risk of mortality to the
patient, and an ICD should be considered whether
or not syncope is present. However, data showing
that syncope increases the risk of arrhythmic and/
/or total mortality is less clear.
Prior retrospective data show that patients with
syncope and cardiomyopathy who undergo ICD implan-
tation get appropriate ICD activations, irrespective of
whether or not they have a positive electrophysiology
test [16, 18, 39]. ICDs appear to improve survival when
used in patients with cardiomyopathy and syncope
[33, 40]. However, the data are from small, single-
site, retrospective studies and are not definitive.
In a study by Knight et al. [17], 14 syncope
patients with non-ischemic dilated cardiomyopathy
and a negative electrophysiology study were compa-
red with 19 cardiac arrest survivors. All the patients
Figure 2. Electrophysiology study demonstrating markedly abnormal His-Purkinje conduction. Shown are recordings
from surface leads I, aVF V1, V6 and intracardiac recordings from the proximal, mid and distal His bundle electrodes.
Figure 3. Electrophysiology study demonstrating inducible monomorphic ventricular tachycardia following program-
med ventricular stimulation. Shown are recordings from surface leads I, aVF V1 and V6.
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had ICDs implanted. Appropriate ICD shocks oc-
curred in about the same number over a mean fol-
low-up of about 24 to 45 months for both groups,
indicating that patients with cardiac arrest and tho-
se with syncope have a similar risk for ventricular
arrhythmias that may lead to sudden death. On the
other hand, one of the observations was that the
mortality was high in both groups (28% and 32%,
respectively, over the follow-up period) despite an
ICD. Several issues arise from this very small stu-
dy: It remained uncertain whether syncope had
anything to do with the need for ICDs. It is also
unclear if ICDs improve mortality.
Sanchez et al. [33] conducted a blinded matched
case-control analysis of 51 patients with unexpla-
ined syncope, cardiomyopathy and a negative elec-
trophysiology study. Comparing patients who rece-
ived ICDs to those who simply received medical
therapy for their condition, there were a high num-
ber of patients with death or cardiac arrest, and this
number was much greater in those who did not have
an ICD suggesting that patients with ICDs will do
better even if electrophysiology testing is negati-
ve when cardiomyopathy is present. In this study,
appropriate ICD shocks occurred in 26% of the pa-
tients at two years and the conclusion was that ICDs
improve the outcome of patients with unexplained
syncope, ischemic or nonischamic cardiomyopathy
and a negative electrophysiology study. These data
extended the information provided above even for
patients with ischemic cardiomyopathy.
Russo et al. [18] evaluated 46 consecutive pa-
tients with non-ischemic dilated cardiomyopathy
and mean left ventricular ejection fraction of 25%,
who presented with syncope and had ICDs implan-
ted. All patients were on proper medical therapy and
43 of the 46 patients underwent electrophysiology
testing. Only 21% of the patients had inducible su-
stained monomorphic ventricular tachycardia.
When observed over a period of 17 ± 15 months,
33% of the patients had appropriate ICD dischar-
ges, indicating a high-risk group where electrophy-
siology testing may not be of great value. The re-
sults also support the idea that ICDs are better than
conventional medical therapy for patients with non-
ischemic dilated cardiomyopathy and poor left ven-
tricular function who present with syncope.
Results from a prospective registry and a sub-
study of the Antiarrhythmics Versus Implantable
Defibrillators (AVID) Study [14], which evaluated
the impact of ICD therapy in patients with unexpla-
ined syncope, structural heart disease and induci-
ble ventricular tachycardia/ventricular fibrillation
with symptoms, indicated that when an ICD was
used as the treatment, survival for patients presen-
ting with syncope was similar to patients who pre-
sented with ventricular tachycardia, and was bet-
ter than for ventricular tachycardia patients treated
with an antiarrhythmic drug. Mortality events in the
sub-study were marginally predicted by ejection
fraction (p = 0.06) but not by the type of ventricu-
lar arrhythmia induced in the electrophysiologic
study. A significant predictor of increased mortali-
ty in the registry was age (p = 0.003), and of redu-
ced mortality was treatment with ICD (p = 0.006).
The authors concluded that ICD should be consi-
dered as primary therapy in patients with unexpla-
ined syncope, structural heart disease and induci-
ble ventricular tachycardia/ventricular fibrillation at
electrophysiologic study.
Based on the above-mentioned data, the most
recent ACC/AHA/ESC guidelines indicate that he-
art failure patients with syncope should be consi-
dered for an ICD [41]. The ACC/AHA/NASPE 2002
guidelines [42] include this class-I indication for an
ICD: syncope of undetermined origin with clinical-
ly relevant, hemodynamically significant, sustained
ventricular tachycardia or ventricular fibrillation
induced at electrophysiology study when drug the-
rapy is ineffective, not tolerated or not preferred
(level of evidence: B). Despite these guidelines,
electrophysiology study may not be a good predic-
tor of outcome and may not indicate who is or is not
at risk of a life threatening arrhythmia. No data sup-
port use of any specific drug therapy to reduce the
risk of arrhythmias in syncope patients. A class-II
indication for an ICD includes syncope in patients
with advanced structural heart disease in which
thorough invasive and non-invasive investigation
has failed to define the cause for syncope (level of
evidence: C). The 2006 ACC/AHA/ESC 2006 guide-
lines [41] have the following class-IIa indication for
an ICD: patients with unexplained syncope, signi-
ficant left ventricular dysfunction and non-ischemic
dilated cardiomyopathy, who are receiving chronic
optimal medical therapy even without electrophy-
siology testing (level of evidence: C). Again, there
are no randomized controlled clinical trials that have
carefully evaluated ICD use in patients with struc-
tural heart disease and syncope.
Data from SCD-HeFT have shed new light re-
garding the use of ICDs in such patients [22]. When
comparing patients receiving amiodarone or place-
bo to ICD, while syncope was associated with a gre-
ater risk for all-cause and cardiovascular death, the
ICD group had the same, if not greater, risk for de-
ath than the amiodarone or placebo group. Syncope
predicted appropriate ICD shocks (hazard ratio 2.91,
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p = 0.001). Despite the fact that the ICD popula-
tion with syncope received more ICD shocks than
the patient group that did not have syncope, they
did not benefit in the sense that they still had a risk
of death as great as or even greater than the amio-
darone and placebo arm of the study. The patients
with ICDs had backup bradycardia pacing at 34 be-
ats per minute. This makes the lack of benefit in
the ICD group even more intriguing as asystole did
not appear to be the mechanism responsible for
syncope or death. Recurrent syncope occurred at
the same rate, independent of the treatment arm.
This highlights the fact that heart failure patients
are sick and may develop hemodynamic problems
that could explain syncope.
Etiology of syncope in
patients with cardiomyopathy
The presumed causes for syncope in the SCD-
-HeFT trial [22] were orthostatic hypotension, ven-
tricular tachycardia and other causes, but in two-
thirds of the population, the etiology for syncope
was either unknown or due to a variety of poten-
tially explainable but ultimately unverifiable causes
(Table 2). In fact, it is even possible that patients
with heart failure could have an extreme form of
neurocardiogenic syncope. Recent tilt table test data
support the fact that heart failure patients may be at
increased risk of neurocardiogenic syncope [29].
The SCD-HeFT data should be viewed in light
of the prospective study by Alboni et al. [24], in
which many patients with suspected or diagnosed
heart disease thought to cause syncope ultimately
were found not to have a cardiac cause for synco-
pe. About half of them had neurally mediated or
neurocardiogenic syncope despite the fact that they
had an underlying cardiac diagnosis [24].
There are many reasons why a patient with
heart failure, even with an ICD, can pass out. The-
se patients may have spontaneous ventricular ta-
chycardia treated by the ICD and can have syncope
prior to ICD discharge. They may have untreated
undetected ventricular tachycardia that are below
the rate cutoff, and this may even be provoked by
the ICD. There may be a ventricular tachyarrhyth-
mia or a bradyarrhythmia that was missed due to
lead or device malfunction or programming error.
On the other hand, it is possible that another arr-
hythmia, such as atrial fibrillation below the ICD
rate cutoff or even ventricular ectopy that is frequ-
ent enough, may cause hemodynamic compromise
resulting in syncope. It could also be that syncope
in this population represents a substantially poorer
substrate that could lead to hemodynamic collapse
that could not be detected or corrected by the ICD [22].
Alternatively, syncope may be due to another cau-
se unrelated to an arrhythmia whatsoever. Thus,
identifying the cause of syncope in a heart failure
patient, even with a sophisticated monitoring devi-
ce like the ICD, can be very challenging at times.
Consider a 43-year-old female with recurrent
syncope, dilated cardiomyopathy, a left ventricular
ejection fraction of 32%, left bundle-branch block
and NYHA class-II heart failure. She has recurrent
syncope despite an ICD implantation. No electro-
physiology study was performed before the ICD
implant. An electrophysiology study was ultimate-
ly performed due to recurrent syncope after the ICD
implant. It showed inducible supraventricular tachy-
cardia below the ICD rate cutoff. The tachycardia
caused hypotension and resulted in syncope in the
electrophysiology lab. Ablation of the supraventri-
cular tachycardia stopped recurrent syncope. Con-
trary to guidelines [41], electrophysiology studies
can be of value in the diagnosis of the etiology of
syncope even if implantation of an ICD is planned.
With prophylactic ICD use, the tendency is to
become relatively lax regarding complete patient
evaluation for syncope. It is possible that the pa-
tient has an easily correctable cause for syncope,
and that should be understood and should be inde-
pendent of simply implanting an ICD. A full evalu-
ation is still required and must include a complete
history and physical examination. Other testing ap-
propriate for the patient should be considered. Pa-
tients with heart failure and syncope do not neces-
sarily benefit from or require an ICD, at least not
Table 2. Presumptive causes for all post-rando-
mization syncopal episodes (458 episodes












*Cardiac arrest defined as loss of consciousness necessitating cardio-
pulmonary resuscitation and/or transthoracic defibrillation. The other
categories were classified based on clinical judgment of the local
investigator.
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immediately. Standard evaluation rules in this regard
still apply and it might be that an ICD is not adequate
therapy or perhaps that it is overkill for these patients.
One should also be aware that there are many
overlapping syndromes that can be present in
a heart failure patient, resulting in syncope. Consi-
der an 85-year-old male who is brought to the emer-
gency room after a falling episode. It was not clear
whether he passed out or tripped on a rug. On cli-
nical assessment, he is found to have orthostatic
hypotension and has been taking nifedipine for hy-
pertension. Even if he has a left ventricular ejec-
tion fraction of 30%, left bundle-branch block, evi-
dence for heart failure, and inducible ventricular
tachycardia on electrophysiology testing, there are
several concerns about simply implanting an ICD
in this elderly man. It is also possible that proper
treatment by changing medications might prevent
the syncope and then a proper decision could be
made about prophylactic use of an ICD in this pa-
tient who may otherwise be relatively free from
ventricular arrhythmias that could cause syncope.
Consider an elderly demented man who has
frequent episodes of syncope. He has been seen by
several internists and cardiologists for left ventri-
cular dysfunction. Monitoring is negative but the
episodes continue. If is of note that he takes phe-
nobarbital, haloperidol, diazepam and acetamino-
phen with codeine, and does not remember how
much he takes. Simply by stopping these medica-
tions he stopped passing out. Therefore, ICDs are
not always the answer to the problem of syncope
in the heart failure patient.
Driving restrictions
A major concern about patients with heart fa-
ilure and syncope is restriction of driving. These
patients should be strictly prevented from commer-
cial driving, whether or not they have an ICD, until
the etiology can be identified and completely tre-
ated. This restriction may be lifted later when the
cause for syncope is known for certain and the pro-
blem can be corrected.
A standard recommendation [43] in the heart
failure population with regard to non-commercial
driving is a six-month restriction from driving after
the ICD is implanted, when syncope is present.
However, patients receiving ICDs for primary pre-
vention who have no symptoms such as syncope can
drive within 1 week after device implantation.
These recommendations are supported by results
from the AVID trial that found that people who
drove against medical advice after resuscitated
ventricular tachycardia/ventricular fibrillation had
a frequency of automobile accidents that was
much less than the general driving population of
the United States (3.4% per year vs. 7.1% per
year). However, these were patients who did not
have syncope [44].
Patients with syncope and heart failure will
probably need to be restricted, at least for a short
time, from driving and other potentially dangerous
activities.
Back to our original patient
— What are the chances that this patient’s syn-
copal event is cardiac in origin?
Available data indicates that this patient has up
to a 40% chance that his syncope may be cardiac in
origin. However, this may be difficult to prove.
— How predictive is this syncopal episode with
respect to this patient’s risk of death?
Syncope in this patient predicts a higher risk
of all-cause and cardiovascular mortality and may
increase his risk of sudden death.
— Would this patient benefit from implantation of
an ICD? If so, should this be done immediately
or after proper medical therapy?
The question as to whether this patient ne-
eds an ICD is a difficult one to answer. The data
remain controversial with no uniform consensus.
A thorough evaluation and aggressive heart failu-
re therapy is warranted, but whether this will re-
duce recurrent syncope and reduce the risk of sud-
den death is unclear. This patient should be tre-
ated medically, as is appropriate for heart failure,
and undergo ICD implantation based on current
guidelines and studies showing benefit of ICD the-
rapy in patients with severely reduced left ventri-
cular function that persists despite optimal medi-
cal therapy. There is no evidence that a more ag-
gressive approach should be taken for the newly
diagnosed heart failure patient with syncope. It is
likely that such a patient with syncope and recen-
tly diagnosed heart failure with severely impaired
left ventricular ejection fraction would undergo
ICD implantation before hospital discharge. Howe-
ver, an alternative approach involving the place-
ment of an implantable loop recorder is not unre-
asonable based on available data.
Conclusions
Syncope is a common problem in patients with
heart failure. Syncope is a predictor of death in pa-
tients with heart failure, but the underlying mecha-
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nisms responsible for this increased risk remain
unresolved [22].
The key to proper management of the heart
failure patient with syncope involves careful clinical
assessment of the symptoms and appropriate treat-
ment for heart failure. Ultimately, the goals of treat-
ment are to prevent sudden death and total mortali-
ty and to reduce the risk of recurrent syncope.
ICDs may reduce the risk of arrhythmic death
in heart failure patients with syncope but may not
necessarily improve survival since syncope may be
due to another mechanism that is not completely
understood.
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